In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exelixis signs debt deal with Deerfield; expired

Executive Summary

Under a facility it is setting up with several funds of the investment group Deerfield Management, Exelixis (clinical-phase cancer candidates) has the option to borrow up to $150mm at 6.75% over the next 18 months.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Financing
    • Convertible Debt
    • Other
    • Private Placement

Related Companies